Release Details

CARLSBAD, Calif., April 28 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc., (Nasdaq: ISIS) announces the following webcast:

What: Isis Pharmaceuticals First Quarter 2005 Financial Results



When: Thursday, May 5, 2005, at 11:00 a.m. (ET) / 8:00 a.m.(PT)



Where: www.isispharm.com



How: Live on the Internet. Simply log onto our website listed above.



Contact: Claudine Prowse, Ph.D.
Investor Relations and Corporate Communications
(760) 603-2331

If you are unable to participate during the live event, a replay of the webcast will be available at www.isispharm.com for up to 30 days.

Isis Pharmaceuticals, Inc. is exploiting its expertise in RNA to discover and develop novel human therapeutic drugs for its pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has 11 antisense products in development to treat metabolic, cardiovascular and inflammatory diseases, and cancer. Through its Ibis division, Isis is developing a system to identify infectious organisms. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of more than 1,500 issued patents worldwide. Additional information about Isis is available at http://www.isispharm.com.

This webcast alert includes forward-looking statements regarding our business, the financial position of Isis Pharmaceuticals, and the therapeutic and commercial potential of our technologies and products in development. Any statement describing our goals, expectations, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement, including those statements that are described as Isis' clinical goals. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, in developing and commercializing technology and systems used to identify infectious agents, and in the endeavor of building a business around such products and services. Our forward-looking statements also involve assumptions that, if they never materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. Although our forward-looking statements reflect the good faith judgment of our management, these statements are based only on facts and factors currently known by us. As a result, you are cautioned not to rely on these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in Isis' Annual Report on Form 10-K for the year ended December 31, 2004, which is on file with the U.S. Securities and Exchange Commission (SEC), and available from the Company.

SOURCE Isis Pharmaceuticals, Inc.
04/28/2005
Web site: http://www.isispharm.com
(ISIS)
04/28/2005 07:55 EDT http://www.prnewswire.com